SCHEMBL5453324

SCHEMBL5453324

CCc1c(NC)nc(N2CCOCC2)nc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
HTT P42858 1/20 0.43
MAPK1 P28482 4/20 0.43
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
GAA P10253 2/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.39
NUDT1 P36639 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PIK3CA P42336 2/20 0.39
MTOR P42345 2/20 0.39
PIK3CG P48736 2/20 0.39
KCNQ3 O43525 1/20 0.38
KCNQ2 O43526 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445110 0.83 NUDT1 (0.51) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5452783 0.83 NUDT1 (0.51) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5457161 0.81 KDM4E (0.42) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5452827 0.79 NUDT1 (0.47) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5450737 0.79 ALDH1A1 (0.47) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5457164 0.78 NUDT1 (0.46) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5458262 0.71 NUDT1 (0.50) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5455711 0.69 ALDH1A1 (0.48) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL759027 0.69 KDM4E (1.00) KDM4EALDH1A1L3MBTL1HTTMAPK1
SCHEMBL5450960 0.68 HRH4 (0.42) KDM4EALDH1A1HTTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259849-A1 Azine-Carboxamides as Anti-Cancer Agents ASTRAZENECA AB (SE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259849-A1 Azine-Carboxamides as Anti-Cancer Agents ARAF, BRAF, RAF1 KDM4E 521/4885ALDH1A1 309/4885L3MBTL1 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.